CERS on Nasdaq
CERUS CORP
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with ORTHOPEDIATRICS CORP, LEMAITRE VASCULAR INC or TREACE MEDICAL CONCEPTS, INC., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-3.7%Operating margin3
-6.7%Net margin3
16.1%Revenue growth, 20253
-24.3%Return on equity3
$1.1MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 88% of the revenue CERUS CORP broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Product | $156.4M | $180.3M | $206.1M |
| Government Contract | $30.4M | $21.1M | $27.7M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Selling, general and admin35¢$80.9M
- Other costs65¢$152.5M
- Income tax0¢$354.0K
Out of $233.8M in revenue.3 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending77¢$3.7M
- Kept or used elsewhere23¢$1.1M
Out of $4.8M of cash from operations.3
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $233.8M | $201.3M | $186.8M |
| Research and development | $67.7M | $58.9M | $67.6M |
| Selling, general and administrative | $80.9M | $75.9M | $75.5M |
| Restructuring | $3.7M | ||
| Total operating expenses | $148.6M | $134.8M | $146.9M |
| Loss from operations | -$8.7M | -$14.2M | -$30.1M |
| Foreign exchange (loss) gain | -$1.3M | $370.0K | -$648.0K |
| Interest expense | -$8.3M | -$8.9M | -$8.4M |
| Other income, net | $3.0M | $2.0M | $1.8M |
| Total non-operating expense, net | -$6.6M | -$6.5M | -$7.3M |
| Loss before income taxes | -$15.3M | -$20.8M | -$37.3M |
| Provision for income taxes | $354.0K | $205.0K | $325.0K |
| Net loss | -$15.6M | -$21.0M | -$37.6M |
| Net loss attributable to noncontrolling interest | -$10.0K | -$43.0K | -$158.0K |
| Net loss attributable to Cerus Corporation | -$15.6M | -$20.9M | -$37.5M |
| Basic | -$0.08 | -$0.11 | -$0.21 |
| Diluted | -$0.08 | -$0.11 | -$0.21 |
| Basic | 190.6M shares | 184.6M shares | 180.3M shares |
| Diluted | 190.6M shares | 184.6M shares | 180.3M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Cash and cash equivalents | $20.0M | $20.3M |
| Short-term investments | $62.9M | $60.2M |
| Accounts receivable, net | $30.4M | $29.8M |
| Current inventories | $56.1M | $38.1M |
| Prepaid and other current assets | $5.0M | $3.6M |
| Total current assets | $174.4M | $152.0M |
| Property and equipment, net | $9.2M | $7.2M |
| Operating lease right-of-use assets | $10.1M | $8.4M |
| Goodwill | $1.3M | $1.3M |
| Restricted cash | $639.0K | $1.1M |
| Non-current inventories | $15.1M | $14.1M |
| Other assets | $11.0M | $16.8M |
| Total assets | $221.9M | $200.9M |
| Accounts payable | $28.0M | $21.7M |
| Accrued liabilities | $25.3M | $18.9M |
| Debt current | $43.3M | $19.3M |
| Operating lease liabilities current | $2.9M | $2.3M |
| Deferred revenue | $1.3M | $1.4M |
| Total current liabilities | $100.8M | $63.6M |
| Debt non-current | $40.5M | $64.9M |
| Operating lease liabilities non-current | $10.2M | $11.7M |
| Other non-current liabilities | $5.4M | $3.9M |
| Total liabilities | $156.9M | $144.0M |
| Common stock, $0.001 par value; 400,000 and 400,000 shares authorized; 192,142 and 185,766 shares issued and outstanding at December 31, 2025 and 2024, respectively | $192.0K | $186.0K |
| Additional paid-in capital | $1.1B | $1.1B |
| Accumulated other comprehensive loss | -$156.0K | -$400.0K |
| Accumulated deficit | -$1.1B | -$1.1B |
| Total Cerus Corporation stockholders' equity | $64.2M | $56.1M |
| Noncontrolling interest | $741.0K | $751.0K |
| Total liabilities and stockholders' equity | $221.9M | $200.9M |
| Preferred stock, par value | $0.00 | $0.00 |
| Preferred stock, shares authorized | 5.0M shares | 5.0M shares |
| Preferred stock, shares issued | 0 shares | 0 shares |
| Preferred stock, shares outstanding | 0 shares | 0 shares |
| Common stock, par value | $0.00 | $0.00 |
| Common stock, shares authorized | 400.0M shares | 400.0M shares |
| Common stock, shares issued | 192.1M shares | 185.8M shares |
| Common stock, shares outstanding | 192.1M shares | 185.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$15.6M | -$21.0M | -$37.6M |
| Depreciation and amortization | $1.4M | $1.9M | $2.6M |
| Stock-based compensation | $22.9M | $22.9M | $20.3M |
| Non-cash operating lease cost | $2.5M | $2.5M | $2.3M |
| Net (gain) loss on sale of available-for-sale securities | -$6.0K | $7.0K | $54.0K |
| Unrealized gain on investments | -$204.0K | -$135.0K | -$170.0K |
| Loss on disposal of fixed assets | $3.0K | $65.0K | |
| Impairment charges for facilities consolidation | $0 | $0 | $1.7M |
| Non-cash interest expense | $398.0K | $398.0K | $374.0K |
| Foreign currency remeasurement loss (gain) | $290.0K | -$388.0K | -$685.0K |
| Accounts receivable | -$396.0K | $5.5M | -$1.1M |
| Inventories | -$14.7M | $7.0M | -$14.9M |
| Prepaid and other assets | -$1.6M | -$3.0M | -$994.0K |
| Accounts payable | $5.7M | -$1.5M | -$7.3M |
| Accrued liabilities and other non-current liabilities | $4.3M | -$2.2M | -$9.1M |
| Deferred revenue | -$124.0K | -$603.0K | $1.4M |
| Net cash provided by (used in) operating activities | $4.8M | $11.4M | -$43.2M |
| Capital expenditures | -$3.7M | -$2.8M | -$4.6M |
| Purchases of investments | -$42.8M | -$43.0M | -$2.5M |
| Proceeds from maturities and sale of investments | $40.3M | $37.7M | $15.7M |
| Net cash (used in) provided by investing activities | -$6.2M | -$8.1M | $8.6M |
| Net proceeds from equity incentives | $595.0K | $804.0K | $925.0K |
| Net costs from public offerings | -$35.0K | -$137.0K | -$175.0K |
| Net (payments on) proceeds from revolving line of credit | -$329.0K | -$703.0K | $5.1M |
| Proceeds from loans, net of issuance costs | $5.0M | $4.8M | |
| Net cash provided by financing activities | $231.0K | $5.0M | $10.7M |
| Effect of exchange rates on cash, cash equivalents, and restricted cash | $336.0K | -$191.0K | -$128.0K |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -$761.0K | $8.0M | -$24.0M |
| Cash paid for interest | $8.5M | $9.3M | $9.2M |
| Cash paid for income taxes | $301.0K | $356.0K | $322.0K |
Recent filings
- Aug 17, 2026144
- Aug 17, 20264
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 2026SCHEDULE 13G/A
- Aug 13, 2026SCHEDULE 13G/A
- Jul 30, 20268-K
- Jul 30, 202610-Q
- Jul 30, 2026S-8
- Jul 20, 20264
- Jul 16, 2026144
- Jul 10, 20268-K
- Jul 2, 20264
- Jul 2, 20264
- Jul 2, 20264
- Jul 2, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARCERUS CORP filings on SEC EDGAR
- 2SEC EDGARCERUS CORP filings on SEC EDGAR
- 3SEC EDGARCERUS CORP 10-K for fiscal 2025
- 4SEC EDGARCERUS CORP 10-K for fiscal 2019
- 5SEC EDGARCERUS CORP 10-K for fiscal 2020
- 6SEC EDGARCERUS CORP 10-K for fiscal 2021
- 7SEC EDGARCERUS CORP 10-K for fiscal 2022
- 8SEC EDGARCERUS CORP 10-Q for fiscal 2026
- 9SEC EDGARCERUS CORP 10-Q for fiscal 2026
- 10SEC EDGARCERUS CORP 10-K for fiscal 2019